Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

333.91 -1.15 (-0.34%)
Streaming Delayed Price Updated: 1:38 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Krystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100M ↗
Krystal Biotech, Inc. (NASDAQ: KRYS) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV)  
Via Benzinga
News headline image
Analyst Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
News headline image
Expert Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
What Will AbbVie Buy Next? ↗
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8
Via Investor Brand Network
News headline image
3 Biotech Stocks to Buy Before the Breakout ↗
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
News headline image
2 Soaring Stocks With More Upside Potential ↗
Are these mid-cap stocks giants in the making? 
Via The Motley Fool
News headline image
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Up 48% in 2023, Is This Biotech Stock a Buy? ↗
How much longer can this biotech's run last? 
Via The Motley Fool
News headline image
Why Shares of Krystal Biotech Are Rising Monday ↗
The company is moving quickly to market its newly approved therapy. 
Via The Motley Fool
News headline image
Analyst Expectations for Krystal Biotech's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Krystal Biotech ↗
 
Via Benzinga
News headline image
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine ↗
 
Via Benzinga
News headline image
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem. 
Via MarketBeat
News headline image
Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
From Option Care Health, Inc.
Via GlobeNewswire
News headline image
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment ↗
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with  
Via Benzinga
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder ↗
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic  
Via Benzinga
News headline image
2 Risky Stocks That Could Soar in 2023 ↗
These "exciting" companies aren't for everyone. 
Via The Motley Fool
News headline image
Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles ↗
 
Via Benzinga
News headline image
NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday ↗
Needham cut the price target for Wix.com Ltd. (NASDAQ: WIX) from $125 to $120. Needham analyst Bernie McTernan maintained a Buy rating. Wix.com shares dropped 3.2% to close at $78.09 on Friday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023 ↗
 
Via Benzinga
News headline image
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗
 
Via Benzinga
News headline image
Have A Look At William Blair's Top Biotech Picks For 2023 ↗
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
News headline image
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond ↗
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
News headline image
SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International ↗
Goldman Sachs raised the price target on Mettler-Toledo International Inc. (NYSE: MTD) from $1,120 to $1,335. Goldman Sachs analyst Matthew Sykes upgraded the stock from Sell to Neutral. Mettler-Toledo... 
Via Benzinga
News headline image
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25% ↗
  SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.